We recently compiled a list of the Top 10 Oncology Stocks to Buy Now. Merck & Co., Inc. tops our list for being one of the best cancer stocks.
TheFly reported on January 8 that Wolfe Research analyst Alexandria Hammond upgraded MRK to Outperform from Peer Perform with a $135 price target. The firm described the five-year revenue outlook as “attractive” and stated that the stock is “poised for a breakout” after accretive M&A and ahead of a catalyst-rich era after integrating MRK’s late-stage pipeline, possible label expansions, and prescriber feedback into its models.
Separately, on January 9, reports emerged that MRK is in active talks to acquire Revolution Medicines for approximately $30 billion.
Merck & Co., Inc. is a leading oncology company driven by its blockbuster immunotherapy Keytruda, with a diversified cancer portfolio spanning immuno-oncology, targeted therapies, and combination regimens, supported by an expanding clinical pipeline and strategic acquisitions to sustain long-term growth.
READ NEXT: 12 Best Multibagger Stocks to Buy Heading into 2026 and 7 Best Rising Tech Stocks to Buy Now.
